Wyeth’s Tygacil “Approvable” For CAP, Pushing Back FDA Action Until December
This article was originally published in The Pink Sheet Daily
FDA seeks more analysis of data on patients with severe illness; Wyeth will submit a "complete response" by June 27.
You may also be interested in...
Analysis sought for treatment indication is similar to what FDA requested for prevention setting.
Firm plans third quarter NDA for mild-to-moderate community-acquired pneumonia indication.
Company tells “The Pink Sheet” DAILY that tigecycline would address needs of patients resistant to other antibiotics, such as J&J’s Levaquin.